Enzalutamide: New alteranative for treatment of prostate cancer metastatic

• Autores: Isabel Gómez Valbuena, Daniele Alioto, Olga Serrano Garrote, José Miguel Ferrari Piquero
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 16, Nº. 5, 2014, págs. 6-6
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective: To analyze the evolution of patients diagnosed with metastatic prostate cancer of a tertiary hospital treated with enzalutamide who have progressed to cancer chemotherapy with docetaxel, and in some cases to abiraterone, and compare them with the results published so far.

    Method: We conducted a retrospective observational of 14 months duration including all patients who started treatment with enzalutamide. To analyze the response, we collected PSA blood levels at the start of therapy and in successive analytical determinations during treatment. The percentage decrease in PSA was calculated using the initial values and the nadir PSA value. Response was considered present if there was a greater than 50% reduction.

    Results: Seven patients were included in the study, with a median age of 74.3 years. The median time from diagnosis to start of therapy with enzalutamide was 11.57 years. The average duration of treatment was 8.14 months. Five patients had a decrease greater than 50% of the initial PSA. The average for this decline was a 72.4% compared to baseline, being the largest decline of 99%.

    Conclusions: Based on the literature and the results of our study, we can say that enzalutamide is a well-tolerated drug in the treatment of patients with metastatic prostate cancer and improves survival time for these patients